Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection

All four adenosine receptor subtypes have been shown to play a role in cardioprotection, and there is evidence that all four subtypes may be expressed in cardiomyocytes. There is also increasing evidence that optimal adenosine cardioprotection requires the activation of more than one receptor subtype. The purpose of this study was to determine whether adenosine A(2A) and/or A(2B) receptors modulate adenosine A(1) receptor-mediated cardioprotection. Isolated perfused hearts of wild-type (WT), A(2A) knockout (KO), and A(2B)KO mice, perfused at constant pressure and constant heart rate, underwent 30 min of global ischemia and 60 min of reperfusion. The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA; 200 nM) was administrated 10 min before ischemia and for the first 10 min of reperfusion. Treatment with CHA significantly improved postischemic left ventricular developed pressure (74 ± 4% vs. 44 ± 4% of preischemic left ventricular developed pressure at 60 min of reperfusion) and reduced infarct size (30 ± 2% with CHA vs. 52 ± 5% in control) in WT hearts, effects that were blocked by the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (100 nM). Treatments with the A(2A) receptor agonist CGS-21680 (200 nM) and the A(2B) agonist BAY 60-6583 (200 nM) did not exert any beneficial effects. Deletion of adenosine A(2A) or A(2B) receptor subtypes did not alter ischemia-reperfusion injury, but CHA failed to exert a cardioprotective effect in hearts of mice from either KO group. These findings indicate that both adenosine A(2A) and A(2B) receptors are required for adenosine A(1) receptor-mediated cardioprotection, implicating a role for interactions among receptor subtypes.     

慈溪麦冬甙A和B的结构

从浙江慈溪产中药麦冬（Ｏｐｈｉｏｐｏｇｏｎ ｊａｐｏｎｉｃｕｍ）中分离得到２个新的Ｃ２７甾体甙－－慈溪麦冬甙Ａ（２）和Ｂ（３）以及已知甙ｏｐｈｉｏｇｅｎｉｎ３－氧－α－Ｌ－鼠李糖吡喃基（１→２）「β－Ｄ－木糖吡喃基（１→３）」－β－Ｄ－葡萄糖吡喃甙（２）和ｏｐｈｉｏｇｅｎｉｎ ３－氧－α－Ｌ－鼠李糖吡喃基（１→２）「β－Ｄ－木糖吡喃基（１→３）」「β－Ｄ－葡萄糖吡喃基（１→４）」－β－Ｄ－葡萄糖吡     

滇黄芩甙A和B的结构

从龙胆科滇黄芩属植物滇黄芩(Veratrilla baillonii Franch)中分离得到两个新的酮二糖甙,经~1H NMR,~(13)C NMR,FAB-MS,MS,2D NMR,UV,IR等物理方法和化学反应,推定为:2,3,4,7-四甲氧基酮-1-O-β-D-葡萄糖(6←1)-β-D-木糖甙(1)和7-羟基-2,3,4-三甲氧基酮-1-O-β-D-葡萄糖(6←1)-β-D-木糖甙(2),分别命名为:滇黄芩甙A和滇黄芩甙B。     

多重PCR检测奶牛乳腺炎金黄色葡萄球菌粘附素基因clfa A、clfa B、fnbp A和fnbp B

利用多重PCR检测金黄色葡萄球菌粘附素基因clfa A、clfa B、fnbp A和fnbp B的方法,对奶牛乳腺炎金黄色葡萄球菌临床分离株进行聚集因子主效基因的分析。通过设计合成的特异性引物对金黄色葡萄球菌模板进行PCR扩增,将目的基因回收并连接到T载体,鉴定后进行测序验证,然后对本实验室所分离鉴定的金葡菌临床分离株进行多重PCR检测。PCR产物经过电泳成像显示,clfa A和clfa B分别在292bp和205bp处出现特异性条带;fn-bp A和fnbp B分别在524bp和642bp处出现特异性条带。通过对29株金葡菌临床分离株多重PCR检测发现:能扩增出clfa A、clfa B、fnbp A和fnbp B的分别有26株、12株、28株和3株。建立的多重PCR检测金黄色葡萄球菌粘附素基因的方法具有良好的特异性和可靠性,并且发现clfa A和fnbp A基因存在于绝大部分的金黄色葡萄球菌中。     

慈菇蛋白酶抑制剂A和B的活性中心探讨

慈菇蛋白酶抑制A和B（APIA和APIB）是一种双头多功能抑制剂。它们的一级结构和cDNA序列已经被阐明。为了找到它们的活性中心,利用定点诱变的方法将APIB中根据与其他抑制剂家族的序列比较所推断的可能的活性中心残基;Lys^44,Arg^76和Arg87分别用Pro替代,所得到的突变基因分别在酵母分泌体系中得到了表达,与天然的APIB相比,K^44P-APIB对脂蛋白酶的抑制活力没有改变;而R^76P-APIB和R^87P-APIB对胰蛋白酶的抑制活力都分别下降了一半,由原料的抑制两分子变成了一分子,表明Arg^76和Arg^87分别是APIB的两个活性中心残基,而Lys^44则不是,为了证实以上结论,进一步制备了另外3种突变体（K^44P-R^76P-APIB,K^44P-R^87P-APIB,R^76P-R^87P-APIB)。在每个突变体中,3个可能的活性位点中只保留1个,有关的抑制活力测定表明,K^44P-R^76P-APIB(只保留Arg^87)和K^44P-R^87P-APIB(只保留Arg^76)分别只抑制一分子胰蛋白酶,而R^76P-R^87P-APIB(只保留Lys^44)对胰蛋白酶基本不抑制,从而肯定了以上结论,经过测定,两个突变体K^44P-R^87P-APIB对胰蛋白酶的抑制常数Ki分别是0.39nmol/L和0.47nmol/L。突变体R^87L-APIB(APIA中87位是Leu)丧失了接近一半的胰蛋白酶抑制活力,但同时对胰凝乳蛋白酶的抑制活性由原来的基本不抑制变成和APIA相同的可以抑制一分子,证明了Leu^87是APIA的抑制胰凝乳蛋白酶的活性中心位点。     

白首乌甙A,B和C的结构

从著名中药白首乌(Cynanchum auricutatum Royle ex Wight)根中分离得到7个C_2(?)体甙。其小4个已知物——wilfosidc C3N (Ⅰ), C1N (Ⅱ), C1G (Ⅲ), K1N (Ⅴ),和另外3个新C_(21)甾体甙,命名为白首乌甙A (Ⅵ),B (Ⅶ),C(Ⅳ) (cynauricusidc A, B,C)。经光谱数据分析和化学反应,证明其结构分别为:开德甙元 3-氧-β D-葡萄糖吡喃基-(1→4)-α-L-加拿大麻糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃基-(1→4)-α-L-迪吉糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃甙(kidjoranin 3-O-β-D-glucopyranosyl-(1→4)-α-L-cymaropyranosy-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside, Ⅵ);萝藦甙元 3-氧-α-L-加拿大麻糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃基-α-L-迪吉糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃甙(metaplexigenin -O-α-L-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-cymaropyranoside,Ⅶ);告达庭 3-氧-β-D-葡萄糖吡喃基-(1→4)-β-L-葡萄糖吡喃基-(1→4)-α-L-加拿大麻糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃基-(1→4-α-L-迪吉糖吡喃基-(1→4)-β-D-加拿大麻糖吡喃基(caudatin 3-O-β-D-glucopyranosy-(1→4)-β-D-glucopyr     

B－E－A毒素的作用机制

Ｂ－Ｅ－Ａ毒素的作用机制毛献荣（中国科学院上海生物化学研究所,上海２０００３１）关键词Ｂ－Ｅ－Ａ毒素,酶活力许多细菌和植物都能产生对哺乳动物有很强细胞毒性的蛋白质,并且它们在结构和作用方式上都很不同。一般根据毒素的主要的破坏位点是在胞液中（通过酶活性...     

从胰岛素A及B链重合成胰岛素

(1)用亚硫酸盐及四硫硫酸盐将胰岛素的硫-硫键拆成S-磺酸基后,再经过离子交换或板型电泳分离,可以得到纯的A及B链。(2)用小白鼠惊厥法检查,S-磺酸型A及B链都不具有生物活力。用过量巯基乙酸将纯的A或B链的S-磺酸基还原为巯基,然后分别将还原型的A或B链溶液(pH 8.5)单独在空气中氧化也不产生活力。但将还原型A及B链混合,在同样条件下氧化时,可以获得有活力的产物。活力一般恢复到原活力的5-10%左右。(3)用还原型的A或B链分别与S-磺酸型的B或A链共同保温都可以得到有活力的产物。(4)将恢复活力的重氧化产物进行提纯的结果得到比活力为每毫克18.4国际单位的结晶。这样所获得的晶体其结晶形状、降血糖性质、电泳性质以及在三种溶剂系统中的比移都和结晶胰岛素相同。(5)以上晶体和结晶胰岛素的胃蛋白酶酶解图谱也基本上相同。     

免疫磁珠技术分离唾液A/B血型抗原并用于吸附血清A/B抗体

目的:应用免疫磁珠分离技术获得具有良好抗原性的A/B血型抗原,并探究其作为ABO血型抗体吸附剂去除A/B抗体的可行性。方法:将含有血型物质的唾液进行预处理,再与包被了抗体的磁珠混合,分离出纯度较高的A/B抗原,运用酶联免疫及凝集抑制试验验证所得抗原的抗原性及是否存在交叉反应。用未纯化A/B抗原和纯化A/B抗原包被磁珠,对含有抗A/B IgM、IgG的血清进行抗体吸附,用纯化A/B抗原对100份来自O型血孕妇的临床血清样本进行抗体吸附,分别评价其吸附效果。结果:纯化抗原与对应抗体反应后,其吸光度显著高于对照组(A抗原与A抗体0.85±0.12 vs.0.27±0.03,P0.01;B抗原与B抗体0.86±0.09 vs.0.24±0.06,P0.01),与其它类型抗体反应后的吸光度值与对照组比较差异无统计学意义(P0.05)。进行红细胞凝集抑制试验时,纯化抗原可显著抑制相应抗体与红细胞的凝集反应,对其它类型抗体与红细胞的凝集没有抑制作用。血清抗体吸附实验表明纯化抗原的吸附效率比未纯化抗原的高(97.00%vs.88.00%,P0.001)。临床样本抗体吸附实验显示,纯化A抗原对抗A IgM/IgG的吸附效率分别为96.88%、98.44%;纯化B抗原对抗B IgM/IgG的吸附效率分别为96.88%、98.44%。结论:磁珠纯化抗原能特异性地与对应抗体结合,有效吸附血清中的血型抗体,有望作为合成A/B抗原的替代品。     

A novel transglycosylating β-galactosidase from Enterobacter cloacae B5

A strain of Enterobacter cloacae B5 producing β-galactosidase with transglycosylation activity was isolated from the soil. Its freeze-thawed cells synthesized galacto-oligosaccharides with a high yield of 55% from 275 g/L lactose at 50 °C for 12 h. A novel β-galactosidase capable of glycosyl transfer was purified from this strain. It was a homotetramer with molecular mass of about 442 kDa. The optimal pH and temperature for hydrolysis activity on o-nitrophenyl-β-d-galactopyranoside (oNPGal) were 6.5–10.5 and 35 °C, respectively. The enzyme showed a wide range of acceptor specificity for transglycosylation and catalyzed glycosyl transfer from oNPGal to various chemicals such as galactose, glucose, fructose, arabinose, mannose, sorbose, rhamnose, xylose, cellobiose, sucrose, trehalose, melibiose, inositol, mannitol, sorbitol and salicin, resulting in novel saccharide yields ranging from 0.8% to 23.5%. A gene encoding the enzyme was cloned and the recombinant enzyme from Escherichia coli had similar transglycosylation activity to the natural enzyme.     

两个新的抗真菌抗生素——Neopeptins A和B

SatomiT. 等(日本)报道,他们在筛选微生物细胞壁生物合成抑制剂时,发现了两个新的抗真菌抗生素NeopeptinsA和B。这两个抗生素都是链霉菌K—710菌株产生的。虽然A和B在理化性质上有差异,但在生物学特性上都能抑制植物致病真菌,而且这种抑制作用还伴有真菌菌丝体的膨胀。盆栽试验结果指出,Neopeptins对黄瓜白粉病有疗效。30ppm对值株的保护效果达90％以上。对细胞壁聚糖合成有抑制作用,能抑制酿酒酵母的β—1,3—葡     

Genetik und Klinik der Hämophilie A und B

Haemophilia A and B are caused by various mutations in the factor VIII (FVIII) and factor IX (FIX) genes, respectively. The clinical course of the disease is variable, dependent on the severity of the molecular defect. Nowadays, haemophilia patients can excellently be treated by plasma-derived or recombinant clotting factor concentrates. Thus, bleeding and its consequences can be almost completely prevented with nearly normal quality of life and life expectancy. The most severe complication of this treatment is the formation of antibodies (inhibitors) against the substituted clotting factor. The risk of inhibitor formation correlates significantly with specific mutation types that preclude endogenous factor VIII/IX protein synthesis and can be as high as 20–50%. The information on the expected clinical course is at present the most important indication for FVIII/IX gene analysis. Knowledge of the underlying FVIII/IX gene mutation further allows a reliable and fast carrier diagnosis in female relatives of patients with haemophilia.     

Vorkommen von ochratoxin A und B in gewürzen

A total of 681 samples of spices, which comprised more than 50 different spice commodities were analysed for the natural occurrence of the mycotoxins ochratoxin A (OTA) and ochratoxin B (OTB). The analytical method involved chloroform extraction, clean-up by immunoaffinity column and HPLC determination of both mycotoxins. OTA and OTB were detected in 143 (21%) and 68 (10%) of the samples, respectively. The highest frequency of occurrence of both mycotoxins detected were in chili (100% for OTA and 55% for OTB), paprika (41% and 15%, respectively) and pepper (23% and 44%, respectively). The toxin concentrations ranged between the detection limit (0.01 ng/g) and 41.8 ng OTA (2.7 ng OTB)/g of chili, 18.9 ng OTA (1.4 ng OTB)/g of paprika and 3.8 ng OTA (4.6 ng OTB)/g of pepper. One sample of a extract of vanilla was found to be positive for OTB at 15 ng/g. However, median values of most samples showed to be below the detection limit. Comparison of the geographical origin of the samples showed that the predominant number of contaminated spices was from Southeast-Asia and India. Highly contaminated paprika samples were found to come from Israel.     

A special issue on NF-κB signaling and function

Since its discovery about 25 years ago,the NF-κB signaling pathway has remained one of the exciting and extensively studied fields of biomedical research.It is...     

不同方式构建A20鼠B细胞淋巴瘤动物模型

目的探索多种方式构建A20鼠B细胞淋巴瘤动物模型及不同方式造模成瘤的特征。方法鼠源性B细胞淋巴瘤细胞株A20经皮下、尾静脉、脾脏和腹腔接种于同源BALB/c小鼠或先接种裸鼠成瘤后组织块移植BALB/c小鼠,观察动物成瘤时间、成瘤率、成瘤部位;取肿瘤组织和动物脏器行石蜡包埋、病理切片、HE染色观察其组织学特点。结果BALB/c鼠皮下注2×10^6组、2×10^7组和裸鼠瘤组织移植BALB/c小鼠组成瘤率皆为100%,成瘤时间分别为（15.29±3.2）d（、7.0±0.82）d和（6.29±0.49）d。BALB/c小鼠尾静脉注射2×106组、2×107组、脾脏注射组、腹腔注射组成瘤率分别为71.4%、100%、71.4%、14.3%,成瘤时间分别为（76.8±12.0）d、（26.1±7.99）d、（32.6±5.99）d和27 d。尾静脉成瘤部位播及肝脏、脾脏、胰腺、肾脏、食道、胃、肠、肠系膜、脑、淋巴结、骨、子宫、肌肉等多脏器和组织。BALB/c鼠A20成瘤组织学类似人弥漫大B细胞淋巴瘤。结论成功构建A20皮下移植瘤模型、血行播散性模型,为利用有免疫功能动物进行B淋巴瘤相关研究提供了实验平台。